MPS-6 syringe pump
Technical characteristics and parameters First, working conditions Environmental conditions: temperature -5 ° C ~ +40 ° C Relative humidity: ≤80% Power supply: AC220V±22v; Built-in power supply: 12V+1.5V, the battery can work continuously for two hours after fully charging (24 hours). Atmospheric pressure: 860hpa-1060hpa Storage temperature: -40C~+55C Power consumption: ≤10VA Flow rate selection: 0.1 ~ 199.9l / h, small increase or decrease of zui 0.1ml / h. The total amount of infusion: 0.1ml ~ 999.9ml, small increase or decrease of Zui 0.1ml. Flow rate error: ± 5% (0.1ml / h ~ < flow rate < 50ml / h) ±3% (50ml/h~ blocking pressure: 40~70kpa Dimensions: 26.8 (L) × 16.2 (W) × 18.7 (H) (cm) Weight: about 4Kg Alarms: self-test, block, bubble, near completion, completion, battery undervoltage, standby, movement. Function: Automatically detect syringe model, total infusion indication, power indication, alarm volume optional, KVO function. Applicable syringe model: 10ml, 20ml, 30ml, 50ml syringe for single use. Third, the characteristics Small size, easy to carry, fast discharge, fast transfer function, convenient for temporary fast delivery, internal nickel-hydrogen backup battery, LCD and digital tube display simultaneously, using two identical or different syringes, two syringes The flow rate and flow rate are controlled separately, the alarm function is accurate and stable, and the processing is promptly reminded. Fourth, the main purpose U first aid, newborn baby, premature infant infusion, regular infusion, etc. Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK) that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma.
Ibrutinib Intermediates,Cas 330786-24-8,Cas 143900-44-1,High Purity Ibrutinib Intermediates Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com
Second, the basic parameters
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma.
We produce a series of complete intermediates for Ibrutinib, intermediate I (CAS No. 330786-24-8) and intermediate II (CAS No. 143900-44-1) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
